Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1903008-80-9
Formula :	C₃₀H₃₄N₈O₃
M.W :	554.64
SMILES Code :	C=CC(NC1=CC(NC2=NC=CC(N3N=C(C4=CC=CC=C4)C(CN(C)C)=C3)=N2)=C(OC)C=C1N5CCOCC5)=O
Synonyms :	YH25448; GNS-1480
MDL No. :	MFCD31728331
InChI Key :	RRMJMHOQSALEJJ-UHFFFAOYSA-N
Pubchem ID :	121269225

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

HEK293/ABCG2	0.25 μM	72 hours	Evaluate the cytotoxicity of Lazertinib, approximately 90% of cells remained viable at 0.25 μM concentration	PMC8897717
HEK293/ABCB1	0.25 μM	72 hours	Evaluate the cytotoxicity of Lazertinib, approximately 90% of cells remained viable at 0.25 μM concentration	PMC8897717
HEK293/Vector	0.25 μM	72 hours	Evaluate the cytotoxicity of Lazertinib, approximately 90% of cells remained viable at 0.25 μM concentration	PMC8897717
S1-MI-80	0.25 μM	72 hours	Evaluate the cytotoxicity of Lazertinib, approximately 90% of cells remained viable at 0.25 μM concentration	PMC8897717
S1	0.25 μM	72 hours	Evaluate the cytotoxicity of Lazertinib, approximately 90% of cells remained viable at 0.25 μM concentration	PMC8897717
KBv200	0.25 μM	72 hours	Evaluate the cytotoxicity of Lazertinib, approximately 90% of cells remained viable at 0.25 μM concentration	PMC8897717
KB	0.25 μM	72 hours	Evaluate the cytotoxicity of Lazertinib, approximately 90% of cells remained viable at 0.25 μM concentration	PMC8897717
HepG2/adr	0.25 μM	72 hours	Evaluate the cytotoxicity of Lazertinib, approximately 90% of cells remained viable at 0.25 μM concentration	PMC8897717
HepG2	0.25 μM	72 hours	Evaluate the cytotoxicity of Lazertinib, approximately 90% of cells remained viable at 0.25 μM concentration	PMC8897717
YU-1092 PDC (EGFR L861Q)	100 nM	24 hours	To evaluate the antitumor activity of the combination of lazertinib and amivantamab in EGFR L861Q mutant PDC, results showed that the combination significantly suppressed the expression of pEGFR/tEGFR and pMET/tMET.	PMC11866483
YUO-139 PDO (EGFR G719S)	10 nM	24 hours	To evaluate the antitumor activity of the combination of lazertinib and amivantamab in EGFR G719S mutant PDO, results showed that the combination significantly suppressed the expression of pEGFR/tEGFR and tMET.	PMC11866483
Ba/F3 cells (EGFR G719A/S768I)	100 nM	72 hours	To evaluate the antitumor activity of the combination of lazertinib and amivantamab in EGFR G719A/S768I mutant cells, results showed that the combination significantly reduced the phosphorylation of EGFR (pEGFR).	PMC11866483
Ba/F3 cells (EGFR S768I)	100 nM	72 hours	To evaluate the antitumor activity of the combination of lazertinib and amivantamab in EGFR S768I mutant cells, results showed that the combination significantly reduced the phosphorylation of EGFR (pEGFR).	PMC11866483
Ba/F3 cells (EGFR G719S)	3 nM	72 hours	To evaluate the antitumor activity of the combination of lazertinib and amivantamab in EGFR G719S mutant cells, results showed that the combination significantly reduced the phosphorylation of EGFR (pEGFR).	PMC11866483
YU-1092 patient-derived cells (EGFR L861Q mutation)	10 nM	72 hours	To evaluate the anti-proliferative effect of Lazertinib on EGFR L861Q mutant cells, results showed significant inhibition of cell viability.	PMC11866483
YUO-139 patient-derived organoid (EGFR G719S mutation)	19.5 nM	10 days	To evaluate the anti-proliferative effect of Lazertinib on EGFR G719S mutant organoids, results showed significant inhibition of organoid viability.	PMC11866483
Ba/F3 cells (EGFR G719A/S768I mutation)	100 nM	72 hours	To evaluate the anti-proliferative effect of Lazertinib on EGFR G719A/S768I mutant cells, results showed significant inhibition of cell viability.	PMC11866483
Ba/F3 cells (EGFR S768I mutation)	100 nM	72 hours	To evaluate the anti-proliferative effect of Lazertinib on EGFR S768I mutant cells, results showed significant inhibition of cell viability.	PMC11866483
Ba/F3 cells (EGFR G719S mutation)	3 nM	72 hours	To evaluate the anti-proliferative effect of Lazertinib on EGFR G719S mutant cells, results showed significant inhibition of cell viability.	PMC11866483
KPP-03 cells	100 nmol/L	72 hours	Evaluate the effect of Lazertinib on KPP-03 cell growth, showing partial inhibition.	PMC11447890
H1975 cells	100 nmol/L	72 hours	Evaluate the effect of Lazertinib on H1975 cell growth, showing partial inhibition.	PMC11447890
HCC4011 cells	100 nmol/L	72 hours	Evaluate the effect of Lazertinib on HCC4011 cell growth, showing partial inhibition.	PMC11447890
PC-9 cells	100 nmol/L	72 hours	Evaluate the effect of Lazertinib on PC-9 cell growth, showing partial inhibition but not complete suppression.	PMC11447890
H1975 NSCLC cells	5 or 50 nM	2 hours	Evaluate the inhibitory effect of Lazertinib on EGFR(L858R/T790M) phosphorylation, results showed Lazertinib was more effective than osimertinib and LN2057 in suppressing pY1068	PMC9743421

Nude mice	HepG2/adr cell xenograft model	Oral	10 mg/kg	Every 3 days, total 6 times	Evaluate the reversal of ABCB1-mediated multidrug resistance by Lazertinib in vivo, results showed Lazertinib significantly reduced tumor size and weight	PMC8897717
BALB/c nude mice	Ba/F3 EGFRG719S xenograft model	Oral	10 mg/kg	Once daily for 27 days	To evaluate the anti-tumor effect of Lazertinib in EGFR G719S mutant xenograft model, results showed a tumor growth inhibition (TGI) value of 26.3% with lazertinib monotherapy.	PMC11866483
Nude mice	PC-9 cell CDX model		3 mg/kg daily	Continuous administration for 31 days	Evaluate the effect of Lazertinib alone or in combination with ONO-7475 and S63845 on PC-9 cell CDX model, showing significant tumor growth inhibition and no tumor regrowth with triple therapy.	PMC11447890

{[proInfo.proName]}

CAS No.: 1903008-80-9

{[proInfo.proName]}

CAS No.: 1903008-80-9

Alternative Products

Product Details of Lazertinib

Safety of Lazertinib

Related Pathways of Lazertinib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT05277701	NSCLC	PHASE2	UNKNOWN	2025-12-24	Yonsei University Health Syste... More >>m, Severance Hospital, Seoul, Korea, Republic of Less <<
NCT05742594	Healthy	PHASE1	COMPLETED	2023-04-03	Celerion, Tempe, Arizona, 8528... More >>3, United States Less <<
NCT05701384	Lung Cancer Stage IV\|EGFR T790... More >>M Less <<	PHASE2	UNKNOWN	2025-01-31	Samsung Medical Center, Seoul,... More >> MA, 06351, Korea, Republic of Less <<
NCT03046992	EGFR Gene Mutation	PHASE1\|PHASE2	UNKNOWN	2025-12-22	Chungbuk National University H... More >>ospital, Cheongju-si, Chungcheongbuk-do, 28644, Korea, Republic of\|The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon-si, Gyeonggi-do, 14647, Korea, Republic of\|National Cancer Center, Goyang-si, Gyeonggi-do, 03080, Korea, Republic of\|CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, 13496, Korea, Republic of\|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of\|The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Gyeonggi-do, 16247, Korea, Republic of\|Gyeongsang National University Hospital, Jinju-si, Gyeongsangnam-do, 52727, Korea, Republic of\|Inje University Haeundae Paik Hospital, Busan, 48108, Korea, Republic of\|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of\|Seoul National University Hospital, Seoul, 03080, Korea, Republic of\|Kangbuk Samsung Hospital, Seoul, 03181, Korea, Republic of\|Asan Medical Center, Seoul, 05505, Korea, Republic of\|Samsung Medical Center, Seoul, 06351, Korea, Republic of\|SMG-SNU Boramae Medical Center, Seoul, 07061, Korea, Republic of\|Severance Hospital, Seoul, Korea, Republic of\|Ulsan University Hospital, Ulsan, 44033, Korea, Republic of Less <<
NCT05112952	Hepatic Impairment\|Healthy	PHASE1	COMPLETED	2022-07-11	CRS Clinical Research Services... More >> Kiel GmbH, Kiel, 24105, Germany\|APEX GmbH, Munchen, 81241, Germany Less <<
NCT05896683	Healthy	PHASE1	COMPLETED	2023-09-01	SGS Belgium NV, Edegem, 2650, ... More >>Belgium Less <<
NCT05377788	Metastatic Lung Non-Small Cell... More >> Carcinoma\|EGFR T790M Less <<		UNKNOWN	2024-06-30	Samsung Medical Center, Seoul,... More >> 06351, Korea, Republic of Less <<
NCT05716672	Non-small Cell Lung Cancer		NOT_YET_RECRUITING	2025-12-31	Inje University Busan Paik Hos... More >>pital, Busan, 47392, Korea, Republic of\|Inje University Haeundae Paik Hospital, Busan, 48108, Korea, Republic of\|Dong-A University Hospital, Busan, 49201, Korea, Republic of\|Pusan National University Hospital, Busan, 49241, Korea, Republic of\|Kosin University Gospel Hospital, Busan, 49267, Korea, Republic of\|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of\|Kyungpook National University Hospital, Daegu, 41944, Korea, Republic of\|Yeungnam University Medical Center, Daegu, 42415, Korea, Republic of\|Daegu Catholic University Medical Center, Daegu, 42472, Korea, Republic of\|Keimyung University Dongsan Medical Center, Daegu, 42601, Korea, Republic of\|Pusan National University Yangsan Hospital, Yangsan, 50612, Korea, Republic of Less <<
NCT05338619	Non-small Cell Lung Cancer Sta... More >>ge III\|EGFR Positive Non-small Cell Lung Cancer\|Non-squamous Non-small-cell Lung Cancer Less <<	PHASE2	RECRUITING	2026-03-02	Kosin University Gospel Hospit... More >>al, Busan, Korea, Republic of\|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of\|Kyungpook National University Medical Center, Daegu, Korea, Republic of\|Chungnam National University Hospital, Daejeon, Korea, Republic of\|Chonnam National University Hospital Hwasun Hospital, Gwangju, Korea, Republic of\|Inha University Hospital, Incheon, Korea, Republic of\|Pusan National University Yangsan Hospital, Pusan, Korea, Republic of\|Asan Medical Center, Seoul, Korea, Republic of\|Hanyang University Seoul Hospital, Seoul, Korea, Republic of\|Koera University Guro Hospital, Seoul, Korea, Republic of\|Korea University Anam Hospital, Seoul, Korea, Republic of\|Kyung Hee University Hospital, Seoul, Korea, Republic of\|Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of Less <<
NCT04075396	Carcinoma, Non-Small-Cell Lung	PHASE1\|PHASE2	COMPLETED	2022-11-14	City of Hope, Duarte, Californ... More >>ia, 91010, United States\|Advent Health Orlando, Orlando, Florida, 32804, United States\|Moffitt Cancer Center, Tampa, Florida, 33612, United States\|Montefiore Medical Center, Bronx, New York, 10461, United States\|Tennessee Oncology, Nashville, Tennessee, 37211, United States\|Hosp Univ Vall D Hebron, Barcelona, 8035, Spain\|Hosp. Gral. Univ. Gregorio Maranon, Madrid, 28009, Spain\|Hosp Virgen de La Victoria, Malaga, 29010, Spain\|The Christie Nhs Foundation Trust, Manchester, M20 4BX, United Kingdom Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed